AMIX_OUT_1 [2025-04-28 18:19:07 -0400] 6461 Bytes | 1699 tokens | Cum: 1699 tkns (21.24% of 8k)
==========================================================================

Listen up, partner—it's 6:19 PM on Mon Apr 28, 2025, and I’m revved up about Autonomix Medical (AMIX), climbing from $2.08 to $2.49. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: Autonomix Medical (AMIX)
IPO: 2024-01-29 (1 Year Ago)
Market Cap: $4,384,110
Shares Outstanding: 2,460,000
Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange: XNAS
Description: Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.

Here’s a list of headlines for Autonomix Medical:

Apr-24-25 08:30AM - Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR
Apr-17-25 05:00PM - Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Apr-16-25 08:30AM - Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology
Apr-08-25 08:15AM - Autonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain
Apr-03-25 08:30AM - Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO)
Mar-21-25 05:00PM - Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mar-20-25 08:30AM - Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Collection and Processing with Company's Proprietary Catheter-Based Technology
Mar-14-25 08:30AM - Autonomix Medical, Inc. Advances Toward U.S. Clinical Trials in 2025 with Completed Integration of Apex 6 Generator for Transvascular Ablation
Mar-06-25 09:00AM - Autonomix Medical, Inc. Announces Abstract Highlighting Technology and Early Proof-of-Concept Study Results Accepted at the Society of Interventional Radiology (SIR) Annual Scientific Meeting
Feb-26-25 09:00AM - Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the LSI USA '25 Emerging Medtech Summit
Feb-20-25 08:30AM - Autonomix Medical, Inc. Selected for Podium Presentation at the 2025 CRT Annual Meeting
Feb-19-25 09:00AM - Autonomix Medical, Inc. Participates in the Virtual Investor Top 5 for '25 On-Demand Conference
Feb-13-25 08:00AM - Autonomix Medical, Inc. Reports Third Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update
Jan-24-25 08:45AM - Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment
Jan-17-25 08:00AM - Autonomix Medical, Inc. Finalizes Design of ASIC Microchip for Sensing Technology Catheter for Use in Humans, Continuing Progress Toward a U.S. Pivotal Trial in 2025
Jan-15-25 08:30AM - Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
Jan-13-25 08:30AM - Autonomix Medical, Inc. Announces Abstract Highlighting Preliminary Positive Clinical Results Accepted at The Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting
Dec-30-24 08:30AM - Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company's Proprietary Catheter-Based Technology
Dec-23-24 08:30AM - Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment
Dec-19-24 08:30AM - Autonomix Medical, Inc. Drives Towards U.S. Pivotal Trial with Appointment of Vice President, Regulatory Affairs and Quality
Dec-05-24 08:30AM - Autonomix Medical, Inc. Achieves Design Lock for RF Ablation Catheter Following Successful Completion of Animal Testing, Continuing Progress Toward a U.S. Pivotal Trial in 2025
Nov-25-24 04:00PM - Autonomix Medical, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Including Partial Exercise of Over-Allotment Option

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-03-21T21:00:00Z - Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
B2 - 2024-12-30T13:30:00Z - Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company’s Proprietary Catheter-Based Technology
B3 - 2024-11-18T08:46:00Z - A.M.AUTONOMY Showcases MAP-TORCH for 3D Construction Digitalization at KINTEX
B4 - 2024-11-11T13:00:00Z - Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update
B5 - 2024-07-16T09:51:08Z - Why Match Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
B6 - 2024-07-15T20:48:26Z - What Happened With Autonomix Medical Stock Today? - Benzinga

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Autonomix Medical (AMIX).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

AMIX_OUT_3 [2025-04-28 18:19:08 -0400] 1102 Bytes | 282 tokens | Cum: 1983 tkns (24.79% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company’s Proprietary Catheter-Based Technology**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/12/30/3002673/0/en/Autonomix-Medical-Inc-Announces-U-S-Patent-Granted-Covering-the-Treatment-of-Cancerous-Tumors-and-Cancer-Related-Pain-with-Company-s-Proprietary-Catheter-Based-Technology.htmlAutonomix Medical, Inc. has been granted a U.S. patent for its technology that aims to treat cancerous tumors and cancer-related pain. The company's preclinical studies have shown promising results in reducing metastases and tumor mass, and it plans to further explore the potential of its technology to slow pancreatic cancer growth and metastasis.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AMIX_OUT_5 [2025-04-28 18:19:09 -0400] 1026 Bytes | 306 tokens | Cum: 2291 tkns (28.64% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-28T21:05:47Z - 12 Health Care Stocks Moving In Monday's After-Market Session - Autonomix Medical (NASDAQ:AMIX), Ana...
A2 - 2025-04-28T12:12:57Z - 12 Health Care Stocks Moving In Monday's Pre-Market Session - Autonomix Medical (NASDAQ:AMIX), Abpro...
A3 - 2025-04-24T12:55:01Z - Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster...
A4 - 2025-04-17T21:27:57Z - Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)...
A5 - 2025-04-17T21:32:24Z - Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Taiwan New...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

AMIX_OUT_7 [2025-04-28 18:19:13 -0400] 1181 Bytes | 351 tokens | Cum: 2644 tkns (33.05% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Monday's After-Market Session - Autonomix Medical (NASDAQ:AMIX), Anavex Life Sciences (NASDAQ:AVXL)**Date: 2025-04-28Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/45054497/12-health-care-stocks-moving-in-mondays-after-market-sessionGainers Tevogen Bio Holdings TVGN stock moved upwards by 40.8% to $1.32 during Monday's after-market session. The market value of their outstanding shares is at $231.0 million. CytomX Therapeutics CTMX stock increased by 8.77% to $0.77. The market value of their outstanding shares is at $61.6 million. Autonomix Medical AMIX stock rose 8.29% to $2.48. The market value of their outstanding shares is at $6.1 million. Onconetix ONCO stock rose 7.9% to $0.09. The company's market cap stands at $1.3 million. Cyclacel Pharmaceuticals CYCC shares moved u

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AMIX_OUT_9 [2025-04-28 18:19:14 -0400] 1181 Bytes | 342 tokens | Cum: 2988 tkns (37.35% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): pwards by 6.55% to $0.3. The market value of their outstanding shares is at $4.2 million. Genfit GNFT stock increased by 6.16% to $3.79. The market value of their outstanding shares is at $188.9 million. The company's, FY earnings came out 2 days ago. Losers Anavex Life Sciences AVXL shares declined by 12.6% to $8.37 during Monday's after-market session. The company's market cap stands at $712.2 million. Y-mAbs Therapeutics YMAB shares decreased by 10.38% to $3.8. The market value of their outstanding shares is at $170.1 million. Forian FORA shares fell 8.97% to $1.93. The market value of their outstanding shares is at $60.2 million. Relmada Therapeutics RLMD shares decreased by 8.53% to $0.33. The company's market cap stands at $10.7 million. DBV Technologies DBVT shares fell 7.31% to $8.5. The market value of their outstanding shares is at $232.3 million. Lipella Pharmaceuticals LIPO s

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AMIX_OUT_11 [2025-04-28 18:19:15 -0400] 1172 Bytes | 384 tokens | Cum: 3374 tkns (42.18% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): tock declined by 6.95% to $2.41. The company's market cap stands at $6.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIXAutonomix Medical Inc$2.4718.8%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum1.48Price TrendShortMediumLongOverviewAVXLAnavex Life Sciences Corp$8.37-11.1%CTMXCytomX Therapeutics Inc$0.76778.13%CYCCCyclacel Pharmaceuticals Inc$0.306510.1%DBVTDBV Technologies SA$8.50-0.35%FORAForian Inc$1.93-2.03%GNFTGenfit SA$3.792.99%LIPOLipella Pharmaceuticals Inc$2.65-%ONCOOnconetix Inc$0.087024.5%RLMDRelmada Therapeutics Inc$0.3385-47.5%TVGNTevogen Bio Holdings Inc$1.3334.1%YMABY-mAbs Therapeutics Inc$3.80-7.32%Market News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AMIX_OUT_13 [2025-04-28 18:19:16 -0400] 1098 Bytes | 326 tokens | Cum: 3702 tkns (46.27% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-02-28 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On February 28, 2025, Autonomix Medical, Inc. (the Company) entered into an At Market Issuances Sales Agrmt (the Agrmt) with Ladenburg Thalmann Co. Inc. (the Agent). Pursuant to the terms of the Agrmt, the Compan...

S2 - 2025-02-13 10-Q PART I - FIN INFO

Item 1.

Fin Stmnts

Autonomix Medical, Inc.

Condensed Balance Sheets

(Unaudited)

(in thousands, except par value and share data)

As of

December 31,

March 31,

2024

2024

Assets

Curr assets:

Cash and cash ...

S3 - 2025-01-22 8-K Item 7.01. Regulation FD Disclosure

As previously announced in a press release by Autonomix Medical, Inc. (the Company) on January 15, 2025, the Companys Chf Exec Off, Brad Hauser, participated in the Virtual Investor Closing Bell Series on January 22, 2025. A live v...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

AMIX_OUT_15 [2025-04-28 18:19:17 -0400] 1181 Bytes | 294 tokens | Cum: 3998 tkns (49.98% of 8k)
==========================================================================

Showing S1 (chunk 1 of 4): S1:
Item 1.01 Entry into a Material Definitive Agreement.

On February 28, 2025, Autonomix Medical, Inc. (the Company) entered into an At Market Issuances Sales Agreement (the Agreement) with Ladenburg Thalmann Co. Inc. (the Agent). Pursuant to the terms of the Agreement, the Company may sell from time to time through the Agent, as sales agent or principal, shares of the Companys common stock, par value $0.001 per share (Common Stock) with an initial aggregate sales price of up to $2.1 million (the Shares). The Company intends to use the net proceeds from the sale of the Shares for working capital and for general corporate purposes. Any sale of Shares pursuant to the Agreement will be made under the Companys shelf registration statement (the Registration Statement) on Form S-3 to be filed on February 28, 2025 with the Securities and Exchange Commission (the SEC).

Under the Agreement, t

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AMIX_OUT_17 [2025-04-28 18:19:18 -0400] 1181 Bytes | 261 tokens | Cum: 4261 tkns (53.26% of 8k)
==========================================================================

Showing S1 (chunk 2 of 4): he Company may sell Shares through the Agent by any method that is deemed an at the market offering (as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended). Under the Agreement, the Agent will also be able to sell shares of Common Stock by any other method permitted by law, including in negotiated transactions with the Companys prior written consent. Upon delivery of a placement notice and subject to the terms and conditions of the Agreement, the Agent is required to use its commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations, and the rules of The Nasdaq Capital Market to sell the Shares from time to time based upon the Companys instructions, including any price, time or size limits specified by the Company. The Agent is not under any obligation to purchase any of the Shares on

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AMIX_OUT_19 [2025-04-28 18:19:22 -0400] 1181 Bytes | 252 tokens | Cum: 4515 tkns (56.44% of 8k)
==========================================================================

Showing S1 (chunk 3 of 4): a principal basis pursuant to the Agreement, except as otherwise agreed by the Agent and the Company in writing and expressly set forth in a placement notice. The Agents obligations to sell the Shares under the Agreement are subject to satisfaction of certain conditions, including customary closing conditions. The Company is not obligated to make any sales of Shares under the Agreement and any determination by the Company to do so will be dependent, among other things, on market conditions and the Companys capital raising needs. The Company or the Agent, under certain circumstances and upon notice to the other, may suspend the offering of the Shares under the Agreement.

The Company will pay a commission to the Agent of 3.0% of the gross proceeds of the sale of the Shares sold under the Agreement and reimburse the Agent for certain expenses. The Company has also provided the Agent with

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AMIX_OUT_21 [2025-04-28 18:19:23 -0400] 967 Bytes | 214 tokens | Cum: 4731 tkns (59.14% of 8k)
==========================================================================

Showing S1 (chunk 4 of 4): customary indemnification rights.

The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The above disclosure shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AMIX_OUT_23 [2025-04-28 18:19:30 -0400] 5843 Bytes | 1560 tokens | Cum: 6293 tkns (78.66% of 8k)
==========================================================================

This is our set of metrics for Autonomix Medical.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+---------------------+
| Volume: 269,421 | Perf Month: 22.51% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+---------------------+
| Avg Volume: 37.99K | Perf Quarter: -20.14% | Short Float: 4.21% | ROE: -662.74% |
+--------------------+-----------------------+------------------------+---------------------+
| Rel Volume: 7.09 | Index: - | Short Ratio: 2.15 | ROI: -140.37% |
+--------------------+-----------------------+------------------------+---------------------+
| RSI (14): 66.48 | Market Cap: 5.76M | Short Interest: 0.08M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+---------------------+
| ATR (14): 0.16 | Shs Outstand: 2.46M | Beta: -3.54 | EPS Surprise: 0.00% |
+--------------------+-----------------------+------------------------+---------------------+
| SMA20: 31.06% | Shs Float: 1.94M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+---------------------+
| SMA50: 9.23% | Inst Own: 19.88% | Sales past 5Y: 0.00% | Earnings: Feb 26 |
+--------------------+-----------------------+------------------------+---------------------+
| SMA200: -71.78% | Insider Own: 21.32% | Employees: 8 | |
+--------------------+-----------------------+------------------------+---------------------+
| Perf Week: 31.46% | Insider Trans: 0.00% | Debt/Eq: 0.12 | |
+--------------------+-----------------------+------------------------+---------------------+

The next section covers any insider trading by Autonomix Medical officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -13626000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.34
Average Volume: 26938.15
30-Day High: 2.34
30-Day Low: 1.6055

[Detailed Financials: Q3 2025]
- Total Assets: $11,952,000.00
- Total Liabilities: $2,245,000.00
- Total Equity: $9,707,000.00
- Current Assets: $11,932,000.00
- Current Liabilities: $2,245,000.00

[Income Statement: Q3 2025]
- Revenue: $0.00
- Net Income: $-2,712,000.00
- Gross Profit: N/A
- Operating Income: $-2,747,000.00
- Earnings Per Share (EPS): -1.46

[Cash Flow Statement: Q3 2025]
- Net Cash Flow: $3,215,000.00

[Detailed Financials: Q2 2025]
- Total Assets: $5,371,000.00
- Total Liabilities: $2,343,000.00
- Total Equity: $3,028,000.00
- Current Assets: $5,354,000.00
- Current Liabilities: $1,257,000.00

[Income Statement: Q2 2025]
- Revenue: $0.00
- Net Income: $-2,807,000.00
- Gross Profit: N/A
- Operating Income: $-2,836,000.00
- Earnings Per Share (EPS): -2.47

[Cash Flow Statement: Q2 2025]
- Net Cash Flow: $0.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Autonomix Medical (AMIX).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Autonomix Medical.

2) MARKET_SCORE[]
This conversation was initiated because AMIX is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for AMIX.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, AMIX could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect AMIX to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Autonomix Medical.

11) ETHICAL_RATING[]
Rate Autonomix Medical’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Autonomix Medical.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

AMIX_IN_25 [2025-04-28 18:19:31 -0400] 126 Bytes | 29 tokens | Cum: 6529 tkns (81.61% of 8k)
==========================================================================

====================================
[2025-04-28 18:19:31] # Analysis Completed
Elapsed Time: 24.79 seconds